banner
EGFR-HER2 inhibitor Mutated EGFR-IN-2, Purity ≥98%
Inquiry

Cat. No.: X24-05-ZQ677

EGFR-HER2 inhibitor Mutated EGFR-IN-2, Purity ≥98%

Synonym: 2050906-97-1; Mutated EGFR-IN-2; SCHEMBL18586074; AKOS040733792; HY-128860; CS-0101439; EGFR-HER2 inhibitor

  • CAS Number: 2050906-97-1
  • Compound CID: 126649709
img
Product Size
1 mg; 5 mg; 10 mg
Price
Datasheet
MSDS
Properties
Description
Mutated EGFR-IN-2 is a compound that blocks the activity of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), both of which are involved in driving the growth and proliferation of certain types of cancer cells. It targets EGFR (ex19del/T790M), EGFR (L858R/T790M), EGFR(L858R), and EGFRex19del.
Molecular Weight
562.64
Molecular Formula
C29H35FN8O3
Targets
EGFR (ex19del/T790M); EGFR (L858R/T790M): <1 nM; EGFR(L858R); EGFRex19del
Form
Lyophilized powder
Purity
≥98%
Identity
Confirmed by NMR/HPLC/MS.
Applications
Mutated EGFR-IN-2 can be used to study its effect as a selective inhibitor of mutant EGFR in cancer treatment.
Publications
Publications (0)

Publications

×
Publications

Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.

As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.

*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.

  • You can upload up to 5 images or ZIP files, and the size of a single file may not exceed 5MB.
Related Products
Quick Links

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.
0